Background: Non-alcoholic fatty liver disease (NAFLD) is a rapidly rising metabolic disorder characterized by excessive hepatic fat accumulation without significant alcohol intake. In Ayurveda, it correlates with Yakṛt dūṣṭi and Meda dhātu vriddhi, conditions involving impaired Agni and Āma formation leading to Srotorodha and hepatic dysfunction. Aim: To evaluate the clinical efficacy of Chitrakadi Vati administered with Takra in patients of NAFLD. Materials and Methods: An open-label clinical study was conducted on 15 diagnosed cases of NAFLD. Each patient received Chitrakadi Vati (500 mg twice daily) with Takra for 60 days. Follow-up and assessment were done on the 90ᵗʰ day, with biochemical (SGOT, SGPT) and ultrasonographic evaluation before and after treatment. Data were statistically analyzed using the Wilcoxon signed-rank and paired t-tests. Results: Significant improvement was observed in clinical symptoms such as Udara śūla, Utkleśa, Aruchi, and Hṛt-kantha-dāha (p < 0.001 for all). Mean SGOT decreased from 80.73 ± 11.44 U/L to 31.00 ± 2.80 U/L, and SGPT from 63.73 ± 6.63 U/L to 28.20 ± 3.69 U/L (p < 0.001). Overall therapeutic effectiveness was 76%.